RecruitingPhase 3NCT03016819
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Studying Alveolar soft tissue sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Advenchen Laboratories, LLC
- Principal Investigator
- Paul CEOAdvenchen Laboratories, LLC
- Intervention
- AL3818(drug)
- Enrollment
- 325 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2028
Study locations (24)
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- University of California Los Angeles, Los Angeles, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- Stanford Medicine Cancer Institute, Stanford, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University St. Louis, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- Thomas Jefferson Hospital - Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Vanderbilt University, Nashville, Tennessee, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03016819 on ClinicalTrials.govOther trials for Alveolar soft tissue sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548177Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06813417CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part SarcomaUniversity of Calgary
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06789081GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)AHS Cancer Control Alberta
- RECRUITINGPHASE2NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03967834Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupInstitut Claudius Regaud
- RECRUITINGPHASE2NCT04332874A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03141684Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaNational Cancer Institute (NCI)